Novavax
NVAX · NASDAQ
Bulios Fair Price
$12.94
40.2% upside
Current Price
$9.23
According to Bulios Fair Price, NVAX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Novavax (NVAX) is a biotechnology company focused on developing innovative vaccine technologies. Their main goal is to provide effective and safe vaccinations against infectious diseases. Currently, Novavax is dedicated to the development of a vaccine for respiratory viruses, including COVID-19. Novavax stock is suitable for investors who closely follow the biotechnology industry and seek opportunities in the healthcare sector. Add Novavax stock to your watchlist on Bulios and stay informed about the latest developments and news regarding this innovative biotech company.
Sector
Healthcare
Industry
Biotechnology
CEO
John Charles Jacobs
Employees
749
Headquarters
Gaithersburg
Upcoming events
Earnings
Upcoming earnings report